<DOC>
	<DOCNO>NCT00628056</DOCNO>
	<brief_summary>Diabetes increase risk heart failure . This mainly due disease blood vessel supply heart muscle and/or high blood pressure , abnormal metabolism may also contribute . We plan study mechanism involve abnormal metabolism , whilst also assess effect drug call Perhexiline improve abnormal metabolism present diabetic patient development heart failure .</brief_summary>
	<brief_title>Mechanisms Responsible Cardiac Skeletal Muscle Energetic Impairment Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Diabetic Cardiomyopathies</mesh_term>
	<mesh_term>Perhexiline</mesh_term>
	<criteria>Diabetes Mellitus ( WHO definition ) HbA1C &lt; 9 No history chest pain No evidence Coronary Artery Disease peripheral vascular disease Left ventricular ejection fraction 50 % No evidence respiratory disease Patients &lt; 16years provide inform consent Evidence significant epicardial coronary artery disease Evidence peripheral vascular disease Abnormal liver function test Clinically apparent peripheral neuropathy Severe chronic renal failure ( creatinine &gt; 250 ) diabetic nephropathy Concomitant use Amiodarone , Quinidine , Haloperidol Selective serotonin ( 5HT ) uptake inhibitor Fluoxetine Paroxetine may inhibit CYP2D6 enzyme Patients statin therapy primary dyslipidemia . Patients recurrent hypoglycaemia Women child bear age use effective contraception ( pregnancy test positive )</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Perhexiline</keyword>
	<keyword>diabetes</keyword>
	<keyword>diabetic cardiomyopathy</keyword>
	<keyword>high energy phosphate kinetics</keyword>
	<keyword>magnetic resonance spectroscopy</keyword>
</DOC>